FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
WHY IT MATTERS
If you have a rare disease, this meeting could influence which diseases the FDA prioritizes for faster drug development in the future—your input or your disease community's input could help shape which conditions get expedited attention.
The FDA is holding a public meeting to get feedback from patients, doctors, and companies about a pilot program called the Commissioner's National Priority Voucher. This program is designed to speed up the development of drugs for diseases that are considered national health priorities. The FDA wants to hear what people think about how the program is working and how it could be improved.
As part of the U.S. Food and Drug Administration’s continuous quality improvement efforts, the agency today published a Federal Register Notice seeking public comment on the Commissioner’s National Priority Voucher pilot program.